Latest Breaking News On - Vigeneron gmb - Page 1 : comparemela.com

ViGeneron Announces First Patient Dosed in Phase 1b Clinical Trial of VG901 for the Intravitreal Treatment of Retinitis Pigmentosa

VG901 is the first and only clinical-stage therapy designed to deliver a functional CNGA1 gene to retinal photoreceptor target cells in retinitis .

United statesVigeneron gmbKatarina stinglShaun brown juliaMc servicesOrphan drug designationGeneron gmbhHereditary retinal degenerationsRare eye diseasesPrincipal investigatorDrug designationRetinitis pigmentosa

EQS-News: ViGeneron GmbH: ViGeneron announces EMA Approval of Clinical Trial Application for VG901, a gene therapy to treat Retinitis Pigmentosa

EQS-News: ViGeneron GmbH: ViGeneron announces EMA Approval of Clinical Trial Application for VG901, a gene therapy to treat Retinitis Pigmentosa
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesVigeneron gmbVigeneron gmbhShaun brown juliaDistribution servicesMc servicesEuropean medicines agencyRegulatory approvalClinical trial applicationRetinitis pigmentosaGeneron gmbhWuxi advanced therapiesCorporate newsRegulatory announcementsAktien sie

ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases

26.04.2022 ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases | adeno-associated virus vector | collaboration

Daiichi sankyoVigeneron gmbDaiichi sankyo companyGeneron gmbhAdeno associated virus vectorDaiichi sankyoEye diseaseGene therapy

DGAP-News: ViGeneron GmbH: ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases

DGAP-News: ViGeneron GmbH / Key word(s): Agreement/Alliance ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases 26.04.2022

Daiichi sankyoShaun brown juliaVigeneron gmbMc servicesDaiichi sankyo companyAgreement allianceDistribution servicesVigeneron gmbhGeneron gmbhGeneron mediaCorporate newsRegulatory announcements

DGAP-News: ViGeneron signs gene therapy strategic collaboration and option agreement with Regeneron for one inherited retinal disease target

DGAP-News: ViGeneron GmbH / Key word(s): Alliance/Agreement ViGeneron signs gene therapy strategic collaboration and option agreement with Regeneron for one inherited retinal disease target 06.04.2022 / 09:00 The issuer is solely responsible for the content of this announcement. ViGeneron signs .

Shaun brown juliaVigeneron gmbMc servicesRegeneron pharmaceuticals incAlliance agreementDistribution servicesVigeneron gmbhGeneron gmbhRegeneron pharmaceuticalsGeneron mediaCorporate newsRegulatory announcementsDgap newsAlliance agreement